Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 8Phase 1/2 3Phase NA 1Phase 4 1Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 8Prostatic Neoplasms 5Small Cell Lung Carcinoma 4Stomach Neoplasms 3Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Recurrence 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Glioma 2Uterine Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Pheochromocytoma 1Peritoneal Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Metastatic Castration-Resistant Prostate Cancer 1Meningioma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × olaparib × Clear all
NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

Lantern Pharma Inc.

Phase 1/2 Active not recruiting
64 enrolled
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡